Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2020 Results - Earnings Call Transcript

-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020-

Jounce Therapeutics Reports Third Quarter 2020 Financial Results

The company announced disappointing news from a phase 2 study.

Why Jounce Therapeutics Stock Is Crashing Today

CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2020 financial results and provide a corporate update before market open on Friday, November 6, 2020. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET.

Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020

Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash

CAMBRIDGE, Mass., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in fireside chats at three upcoming investor conferences in September:

Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September

Gilead Sciences

Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.

Gilead Inks Deal With Jounce to License an Oncology Candidate

Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc.

Why This Gilead Deal Is Huge For Jounce Therapeutics

Shares of Gilead Sciences Inc. GILD, +2.28% were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.

Gilead signs on for another oncology deal, this time with Jounce Therapeutics

  –  Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody  –

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Jounce Therapeutics' (JNCE) CEO Rich Murray on Q2 2020 Results - Earnings Call Transcript

- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., July  31, 2020  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2020 financial results and provide a corporate update before market open on Friday, August 7, 2020. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET.

Jounce Therapeutics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Friday, August 7, 2020

- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells -

Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting

CAMBRIDGE, Mass., June  10, 2020  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020 at 3:00 p.m. ET.

Jounce Therapeutics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference

Agios Pharmaceuticals

Mersana Therapeutics

Sutro Biopharma Inc

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Got $1,000? Buy These 4 Cancer Stocks

CAMBRIDGE, Mass., June  04, 2020  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has regained the worldwide rights to JTX-8064 from Bristol Myers Squibb. JTX-8064 is a highly-selective, potential first-in-class antibody that targets the Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) on macrophages, and was licensed to Celgene in July 2019. As part of its Celgene integration process, Bristol Myers Squibb is streamlining its pipeline and addressing areas of overlap. As a result, Bristol Myers Squibb notified Jounce that the JTX-8064 License Agreement is being terminated.   

Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2020 Results - Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2019 Results - Earnings Call Transcript

Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.

What's in Store for Jounce (JNCE) This Earnings Season?

Jounce Therapeutics: An Attractive Immunotherapy Pick For 2020

Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System

CAMBRIDGE, Mass., Jan.  23, 2020  (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone, M.D., M.S.C.E., to its board of directors.

Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors

Is  (JNCE) Outperforming Other Medical Stocks This Year?

Is Jounce Therapeutics (JNCE) Stock Outpacing Its Medical Peers This Year?

Aegion

Foundation Building Materials

Ichor Hlds

Spartan Motors

Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.

News for Jounce Therapeutics Stock (JNCE)